Ferdinand H. Bahlmann

TL;DR: These findings establish additional mechanisms by which statins may specifically preempt disordered vascular wall pathology and constitute physiological evidence that EPC mobilization represents a functionally relevant consequence of statin therapy.

TL;DR: The notion that diabetic neuropathy results from microvascular ischemia involving the vasa nervorum is supported and the feasibility of a novel treatment strategy for patients in whom peripheral neuropathy constitutes a secondary complication of diabetes is suggested.

TL;DR: Catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor–dependent mechanism, indicating induction of arteriogenesis and postnatal vasculogenesis.

TL;DR: These findings implicate microvascular damage as the basis for toxic neuropathy induced by cisplatin and suggest that local angiogenic gene therapy may constitute a novel prevention or treatment for this disorder without augmenting tumor growth or vascularization.

TL;DR: The data indicate that gene therapy with secretoneurin induces therapeutic angiogenesis, arteriography, and vasculogenesis in the hindlimb ischemia model by a nitric oxide–dependent mechanism.